Borel Fields, Would they relate to Leronlimab's

Borel Fields,

Quote:

---

Would they relate to Leronlimab's role in platelet activation?

---

Indeed !!!.

There are several articles depicting the relationship between RANTES and platelet activation. More specifically megakaryocytes (MK)

https://www.researchgate.net/publication/2864...n/download

They worked with Maraviroc:

Quote:

---

We hypothesized that CCL5 could regulate platelet production by
binding to its receptor, CCR5, on MKs. Maraviroc (CCR5 antagonist) or CCL5 immunodepletion diminished 95% and 70% of the effect of platelet releasate, respectively, suggesting CCL5 derived from platelets is sufficient to drive increased platelet production through MK CCR5.

---

And

Quote:

---

Pretreating the MK cultures with maraviroc prior to exposure to CCL5
reversed the augmented proplatelet formation and ploidy, suggesting that CCL5 increases MK ploidy and proplatelet formation in a CCR5-dependent manner.

---

While you are at it here is another article (JCI): " Bone marrow CD34+ cells and megakaryoblasts secrete β-chemokines that block infection of hematopoietic cells by M-tropic R5 HIV "

https://www.jci.org/articles/view/7779

Quote:

---

Interestingly, the secretion of endogenous chemokines decreased with the maturation of CD34+ cells, although ex vivo, expanded megakaryoblasts still secreted a significant amount of RANTES

---